|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serotonin 5-HT2C receptor is a G-protein coupled excitatory receptor that regulates several biochemical pathways and has been implicated in obesity, mental state, sleep cycles, autism, neuropsychiatric disorders and neurodegenerative diseases.
|
30862860 |
2019 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Since 5-HT2CR is a class A G protein-coupled receptor (GPCR), drug discovery efforts have traditionally pursued the activation of the receptor through synthetic ligands with agonists proposed for the treatment of obesity, substance use disorders and impulse control disorders while antagonists may add value for the treatment of anxiety, depression and schizophrenia.
|
31288724 |
2019 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, POLR1B, POLE3, POLD3, and HTR2C might play important roles in obese PCOS via involvement of pyrimidine metabolism and calcium signaling pathway.
|
29601948 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
The serotonin receptor 2C (5HT2C) is an important drug target to treat obesity and depression.
|
29969651 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
The serotonin (5-HT) 5-HT2A receptor (5-HT2AR) and 5-HT2C receptor (5-HT2CR) in the central nervous system are implicated in a range of normal behaviors (e.g., appetite, sleep) and physiological functions (e.g., endocrine secretion) while dysfunctional 5-HT2AR and/or 5-HT2CR are implicated in neuropsychiatric disorders (e.g., addiction, obesity, schizophrenia).
|
30157263 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Medications targeting 5-hydroxytryptamine (5-HT; serotonin) 2C receptors (htr2c; 5-HT<sub>2C</sub>R) improve obesity.
|
30146485 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
It examines the growing evidence that altered levels of these SNORDs and/or their host-gene transcripts may be a primary cause of Prader-Willi syndrome (PWS; a rare disorder characterized by overeating and obesity) as well as abnormalities in signaling through the 5-HT2C serotonin receptor.
|
28296064 |
2017 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity.
|
23537943 |
2013 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To determine whether LEPR Q223R, LEP -2548G/A and HTR2C -759C/T polymorphisms are associated with obesity and weight change in patients using atypical antipsychotic drugs.
|
21510767 |
2011 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that common HTR2C gene variants are unlikely to have a major role in obesity- and mental health-related traits in the general population.
|
20065966 |
2010 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In patients without the HTR2C -759T allele, presence of the LEP -2548G allele was associated with obesity (odds ratio, 2.88; 95% confidence interval, 1.05-7.95).
|
21105285 |
2010 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The frequency of patients homozygous for the HTR2C haplotype A (-759C, -697G, and 23Cys) was significantly higher among clozapine-treated patients with obesity (BMI >/= 30 kg/m) compared with nonobese patients (P = 0.015; odds ratio, 28; 95% confidence interval, 2-380).
|
19142110 |
2009 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
CTD_human |
The frequency of patients homozygous for the HTR2C haplotype A (-759C, -697G, and 23Cys) was significantly higher among clozapine-treated patients with obesity (BMI >/= 30 kg/m) compared with nonobese patients (P = 0.015; odds ratio, 28; 95% confidence interval, 2-380).
|
19142110 |
2009 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data demonstrate lorcaserin to be a potent, selective, and efficacious agonist of the 5-HT(2C) receptor, with potential for the treatment of obesity.
|
18252809 |
2008 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our aim was to determine the possible association of the -759C/T polymorphism of the 5-HT2C receptor gene with type 2 diabetes and obesity in male and female individuals Caucasian origin.
|
18192901 |
2008 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results indicate that a combined genotype carrying the variant HTR2C:c.1-142948(GT)n 13 repeat allele, the common allele rs3813929 C, the variant allele rs518147 C and the variant allele rs1414334 C is significantly related to an increased risk of obesity (OR 3.71 (95% confidence interval: 1.24-11.12)).
|
17016522 |
2007 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
CTD_human |
Evidence was based on the observation that knock-out mice for the HTR2C receptor gene develop obesity and that many antipsychotics (AP) with potent HTR2C antagonism may induce weight gain in susceptible individuals.
|
17702092 |
2007 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Evidence was based on the observation that knock-out mice for the 5-HT2C receptor gene (HTR2C) develop obesity and that many atypical antipsychotics with potent 5-HT2C antagonism may induce weight gain in susceptible individuals.
|
17291373 |
2007 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Evidence was based on the observation that knock-out mice for the HTR2C receptor gene develop obesity and that many antipsychotics (AP) with potent HTR2C antagonism may induce weight gain in susceptible individuals.
|
17702092 |
2007 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To find informative gene variations, we have also compared the effects of some polymorphisms of the serotonin receptor 2C and 2A in mental disorders, for antipsychotic therapeutic effect, for antipsychotic neuronal side effects, and for obesity.
|
17168843 |
2006 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
We suggest that inconsistent associations between HTR2C and several phenotypes, including obesity, may be due to the LD pattern across the gene in which recombination and gene conversion have been influential.
|
16021472 |
2005 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An HTR2C promoter polymorphism (-759C/T) has been associated with obesity and with weight gain in response to antipsychotic (neuroleptic) drugs.
|
15048662 |
2004 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
The current paper therefore reviews both the pre-clinical and clinical evidence supporting the use of 5-HT(2C) receptor agonists for the treatment of obesity and assesses the developments that have been made in this regard to date.
|
12678838 |
2003 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes.
|
10768099 |
2000 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of a Cys23Ser mutation within the human 5-HT2C receptor gene: no evidence for an association of the mutant allele with obesity or underweight in children, adolescents and young adults.
|
9200673 |
1997 |